Regenerative Medicine Market Research Report: By Type (Cell Therapy, Gene Therapy, Tissue Engineered Products), Application (Musculoskeletal, Wound Care, Oncology, Dental, Ocular) - Global Industry Analysis and Demand Forecast to 2030

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1 Market Segmentation by Type

1.3.2 Market Segmentation by Application

1.3.3 Market Segmentation by Region

1.3.4 Analysis Period

1.3.5 Market Data Reporting Unit

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.1.1 Breakdown of Primary Research Respondents

2.1.1.1 By region

2.1.1.2 By industry participant

2.1.1.3 By company type

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Definition of Market Segments

4.1.1 By Type

4.1.1.1 Cell therapy

4.1.1.1.1 Stem cell therapy

4.1.1.1.1.1 Autologous

4.1.1.1.1.2 Allogenic

4.1.1.1.2 Somatic cell therapy

4.1.1.1.2.1 Autologous

4.1.1.1.2.2 Allogenic

4.1.1.2 Tissue engineered products

4.1.1.2.1 Cell-based

4.1.1.2.2 Others

4.1.1.3 Gene therapy

4.1.1.3.1 Viral

4.1.1.3.2 Non-viral

4.1.2 By Application

4.1.2.1 Musculoskeletal

4.1.2.2 Wound care

4.1.2.3 Oncology

4.1.2.4 Dental

4.1.2.5 Ocular

4.1.2.6 Others

4.2. Market Dynamics

4.2.1 Trends

4.2.1.1 Increasing number of collaborations and partnerships

4.2.1.2 Evolution of the market with product launches

4.2.2 Drivers

4.2.2.1 Technological advancements

4.2.2.2 Increasing interest of government research institutes to establish regenerative medicine as a new medical discipline

4.2.2.3 Rising prevalence of chronic diseases and genetic disorders

4.2.2.4 Shifting demographics are creating higher burden of chronic diseases

4.2.2.5 Involvement of various healthcare companies

4.2.2.6 Increasing demand for organ transplantation

4.2.2.7 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Cost-ineffectiveness of regenerative medicine therapies

4.2.3.2 Lack of attention from pricing and reimbursement authorities

4.2.3.3 Limited access to stem cells

4.2.3.4 Protection of intellectual property rights

4.2.3.5 Safety and ethical issues surrounding stem cell-based therapy

4.2.3.6 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Emerging economies are key opportunities area for market players

4.3. Impact of COVID-19

4.4. Porter’s Five Forces Analysis

4.4.1 Bargaining Power of Buyers

4.4.2 Bargaining Power of Suppliers

4.4.3 Intensity of Rivalry

4.4.4 Threat of New Entrants

4.4.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

5.1. By Type

5.1.1 Cell Therapy Market, by Type

5.1.1.1 Stem cell therapy market, by type

5.1.1.2 Somatic cell therapy market, by type

5.1.2 Gene Therapy Market, by Type

5.1.3 Tissue Engineered Products Market, by Type

5.2. By Application

5.3. By Region

Chapter 6. North America Market Size and Forecast

6.1. By Type

6.1.1 Cell Therapy Market, by Type

6.1.1.1 Stem cell therapy market, by type

6.1.1.2 Somatic cell therapy market, by type

6.1.2 Gene Therapy Market, by Type

6.1.3 Tissue Engineered Products Market, by Type

6.2. By Application

6.3. By Country

Chapter 7. Europe Market Size and Forecast

7.1. By Type

7.1.1 Cell Therapy Market, by Type

7.1.1.1 Stem cell therapy market, by type

7.1.1.2 Somatic cell therapy market, by type

7.1.2 Gene Therapy Market, by Type

7.1.3 Tissue Engineered Products Market, by Type

7.2. By Application

7.3. By Country

Chapter 8. APAC Market Size and Forecast

8.1. By Type

8.1.1 Cell Therapy Market, by Type

8.1.1.1 Stem cell therapy market, by type

8.1.1.2 Somatic cell therapy market, by type

8.1.2 Gene Therapy Market, by Type

8.1.3 Tissue Engineered Products Market, by Type

8.2. By Application

8.3. By Country

Chapter 9. LATAM Market Size and Forecast

9.1. By Type

9.1.1 Cell Therapy Market, by Type

9.1.1.1 Stem cell therapy market, by type

9.1.1.2 Somatic cell therapy market, by type

9.1.2 Gene Therapy Market, by Type

9.1.3 Tissue Engineered Products Market, by Type

9.2. By Application

9.3. By Country

Chapter 10. MEA Market Size and Forecast

10.1. By Type

10.1.1 Cell Therapy Market, by Type

10.1.1.1 Stem cell therapy market, by type

10.1.1.2 Somatic cell therapy market, by type

10.1.2 Gene Therapy Market, by Type

10.1.3 Tissue Engineered Products Market, by Type

10.2. By Application

10.3. By Country

Chapter 11. Competitive Landscape

11.1. Product Benchmarking of Key Players

11.2. Strategic Developments in the Market

11.2.1. Products Launches and Approvals

11.2.2. Acquisitions

11.2.3. Partnerships

Chapter 12. Company Profiles

12.1. Smith & Nephew plc

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.1.3 Key Financial Summary

12.2. 3M Company

12.2.1. Business Overview

12.2.2. Product and Service Offerings

12.2.3. Key Financial Summary

12.3. Integra LifeSciences Holdings Corporation

12.3.1. Business Overview

12.3.2. Product and Service Offerings

12.3.3. Key Financial Summary

12.4. Wright Medical Group N.V.

12.4.1. Business Overview

12.4.2. Product and Service Offerings

12.4.3. Key Financial Summary

12.5. Stryker Corporation

12.5.1. Business Overview

12.5.2. Product and Service Offerings

12.5.3. Key Financial Summary

12.6. Zimmer Biomet Holdings Inc.

12.6.1. Business Overview

12.6.2. Product and Service Offerings

12.6.3. Key Financial Summary

12.7. Novartis AG

12.7.1. Business Overview

12.7.2. Product and Service Offerings

12.7.3. Key Financial Summary

12.8. Amgen Inc.

12.8.1. Business Overview

12.8.2. Product and Service Offerings

12.8.3. Key Financial Summary

12.9. Allergan plc

12.9.1. Business Overview

12.9.2. Product and Service Offerings

12.9.3. Key Financial Summary

12.10. Medtronic plc

12.10.1. Business Overview

12.10.2. Product and Service Offerings

12.10.3. Key Financial Summary

12.11. MiMedx Group Inc.

12.11.1. Business Overview

12.11.2. Product and Service Offerings

12.12. Vericel Corporation

12.12.1. Business Overview

12.12.2. Product and Service Offerings

12.12.3. Key Financial Summary

12.13. Organogenesis Holdings Inc.

12.13.1. Business Overview

12.13.2. Product and Service Offerings

12.13.3. Key Financial Summary

12.14. Misonix Inc.

12.14.1. Business Overview

12.14.2. Product and Service Offerings

12.14.3. Key Financial Summary

12.15. Takeda Pharmaceutical Company Limited

12.15.1. Business Overview

12.15.2. Product and Service Offerings

12.15.3. Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 MARKET SIZE ANALYSIS PERIOD

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2024)

TABLE 5 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2025–2030)

TABLE 6 GLOBAL CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 7 GLOBAL CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 8 GLOBAL STEM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 9 GLOBAL STEM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 10 GLOBAL SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 11 GLOBAL SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 12 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 13 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 14 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2019–2024)

TABLE 15 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2025–2030)

TABLE 16 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2024)

TABLE 17 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2025–2030)

TABLE 18 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION, $M (2019–2024)

TABLE 19 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION, $M (2025–2030)

TABLE 20 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2024)

TABLE 21 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2025–2030)

TABLE 22 NORTH AMERICA CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 23 NORTH AMERICA CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 24 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 25 NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 26 NORTH AMERICA SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 27 NORTH AMERICA SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 28 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 29 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 30 NORTH AMERICA TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2019–2024)

TABLE 31 NORTH AMERICA TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2025–2030)

TABLE 32 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2024)

TABLE 33 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2025–2030)

TABLE 34 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2024)

TABLE 35 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2025–2030)

TABLE 36 EUROPE REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2024)

TABLE 37 EUROPE REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2025–2030)

TABLE 38 EUROPE CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 39 EUROPE CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 40 EUROPE STEM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 41 EUROPE STEM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 42 EUROPE SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 43 EUROPE SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 44 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 45 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 46 EUROPE TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2019–2024)

TABLE 47 EUROPE TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2025–2030)

TABLE 48 EUROPE REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2024)

TABLE 49 EUROPE REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2025–2030)

TABLE 50 EUROPE REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2024)

TABLE 51 EUROPE REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2025–2030)

TABLE 52 APAC REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2024)

TABLE 53 APAC REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2025–2030)

TABLE 54 APAC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 55 APAC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 56 APAC STEM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 57 APAC STEM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 58 APAC SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 59 APAC SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 60 APAC GENE THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 61 APAC GENE THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 62 APAC TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2019–2024)

TABLE 63 APAC TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2025–2030)

TABLE 64 APAC REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2024)

TABLE 65 APAC REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2025–2030)

TABLE 66 APAC REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2024)

TABLE 67 APAC REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2025–2030)

TABLE 68 LATAM REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2024)

TABLE 69 LATAM REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2025–2030)

TABLE 70 LATAM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 71 LATAM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 72 LATAM STEM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 73 LATAM STEM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 74 LATAM SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 75 LATAM SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 76 LATAM GENE THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 77 LATAM GENE THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 78 LATAM TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2019–2024)

TABLE 79 LATAM TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2025–2030)

TABLE 80 LATAM REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2024)

TABLE 81 LATAM REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2025–2030)

TABLE 82 LATAM REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2024)

TABLE 83 LATAM REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2025–2030)

TABLE 84 MEA REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2024)

TABLE 85 MEA REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2025–2030)

TABLE 86 MEA CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 87 MEA CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 88 MEA STEM CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 89 MEA STEM CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 90 MEA SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 91 MEA SOMATIC CELL THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 92 MEA GENE THERAPY MARKET, BY TYPE, $M (2019–2024)

TABLE 93 MEA GENE THERAPY MARKET, BY TYPE, $M (2025–2030)

TABLE 94 MEA TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2019–2024)

TABLE 95 MEA TISSUE ENGINEERED PRODUCTS MARKET, BY TYPE, $M (2025–2030)

TABLE 96 MEA REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2024)

TABLE 97 MEA REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2025–2030)

TABLE 98 MEA REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2024)

TABLE 99 MEA REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2025–2030)

TABLE 100 PRODUCT BENCHMARKING OF KEY PLAYERS

TABLE 101 SMITH & NEPHEW PLC – AT A GLANCE

TABLE 102 SMITH & NEPHEW PLC – KEY FINANCIAL SUMMARY

TABLE 103 3M COMPANY – AT A GLANCE

TABLE 104 3M COMPANY – KEY FINANCIAL SUMMARY

TABLE 105 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – AT A GLANCE

TABLE 106 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – KEY FINANCIAL SUMMARY

TABLE 107 WRIGHT MEDICAL GROUP N.V. – AT A GLANCE

TABLE 108 WRIGHT MEDICAL GROUP N.V. – KEY FINANCIAL SUMMARY

TABLE 109 STRYKER CORPORATION – AT A GLANCE

TABLE 110 STRYKER CORPORATION – KEY FINANCIAL SUMMARY

TABLE 111 ZIMMER BIOMET HOLDINGS INC. – AT A GLANCE

TABLE 112 ZIMMER BIOMET HOLDINGS INC. – KEY FINANCIAL SUMMARY

TABLE 113 NOVARTIS AG – AT A GLANCE

TABLE 114 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 115 AMGEN INC. – AT A GLANCE

TABLE 116 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 117 ALLERGAN PLC – AT A GLANCE

TABLE 118 ALLERGAN PLC – KEY FINANCIAL SUMMARY

TABLE 119 MEDTRONIC PLC – AT A GLANCE

TABLE 120 MEDTRONIC PLC – KEY FINANCIAL SUMMARY

TABLE 121 MIMEDX GROUP INC. – AT A GLANCE

TABLE 122 VERICEL CORPORATION – AT A GLANCE

TABLE 124 ORGANOGENESIS HOLDINGS INC. – AT A GLANCE

TABLE 126 MISONIX INC. – AT A GLANCE

TABLE 128 TAKEDA PHARMACEUTICAL COMPANY LIMITED – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2023)

FIG 8 GLOBAL REGENERATIVE MEDICINE MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 INTENSITY OF RIVALRY

FIG 12 THREAT OF NEW ENTRANTS

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL REGENRATIVE MEDICINE MARKET SNAPSHOT

FIG 15 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2030)

FIG 16 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2030)

FIG 17 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION, $M (2019–2030)

FIG 18 NORTH AMERICA REGENERATIVE MEDICINE MARKET SNAPSHOT

FIG 19 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2030)

FIG 20 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2030)

FIG 21 NORTH AMERICA REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2030)

FIG 22 EUROPE REGENERATIVE MEDICINE MARKET SNAPSHOT

FIG 23 EUROPE REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2030)

FIG 24 EUROPE REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2030)

FIG 25 EUROPE REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2030)

FIG 26 APAC REGENERATIVE MEDICINE MARKET SNAPSHOT

FIG 27 APAC REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2030)

FIG 28 APAC REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2030)

FIG 29 APAC REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2030)

FIG 30 LATAM REGENERATIVE MEDICINE MARKET SNAPSHOT

FIG 31 LATAM REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2030)

FIG 32 LATAM REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2030)

FIG 33 LATAM REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2030)

FIG 34 MEA REGENERATIVE MEDICINE MARKET SNAPSHOT

FIG 35 MEA REGENERATIVE MEDICINE MARKET, BY TYPE, $M (2019–2030)

FIG 36 MEA REGENERATIVE MEDICINE MARKET, BY APPLICATION, $M (2019–2030)

FIG 37 MEA REGENERATIVE MEDICINE MARKET, BY COUNTRY, $M (2019–2030)

FIG 38 SMITH & NEPHEW PLC – REVENUE SPLIT BY PRODUCT FRANCHISE AND GEOGRAPHY (2023)

FIG 39 3M COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 40 INTEGRA LIFESCIENCES HOLDINGS CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 41 WRIGHT MEDICAL GROUP N.V. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 42 STRYKER CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 43 ZIMMER BIOMET HOLDINGS INC. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2023)

FIG 44 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 45 AMGEN INC. – REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2023)

FIG 46 ALLERGAN PLC – REVENUE SPLIT BY PRODUCT SEGMENT (2023)

FIG 47 MEDTRONIC PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 48 VERICEL CORPORATION – REVENUE SPLIT BY PRODUCT (2023)

FIG 49 ORGANOGENESIS HOLDINGS INC. – REVENUE SPLIT BY SEGMENT (2023)

FIG 50 MISONIX INC. – REVENUE SPLIT BY CATEGORY AND GEOGRAPHY (2023)

FIG 51 TAKEDA PHARMACEUTICAL COMPANY LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)